11:55 AM on Friday, January 13 – Dr. Robert A. Preti, President of PCT, will speak in Session 6, "Business Models", about "Considerations in scale up of autologous and allogeneic cell therapies: implications to cost of goods".
BOCEMb 2012 - Noble Financial Capital Markets Equity Conference – January 17-18, 2012, Hollywood, Florida – Hard Rock Hotel 12:00 PM on Wednesday, January 18 – Jason Kolbert, NeoStem's Vice President of Strategic Business Development, will present on NeoStem.
Phacilitate Cell & Gene Therapy Forum 2012 – January 30 - February 1, 2012, Washington DC – The Grand Hyatt2:10 PM on Monday, January 30 – Dr. Sanjin Zvonic, Director, Technology & Business Development, PCT, will present during a session titled "Beyond scale-up: Managing the delivery and bedside integrity of cryopreserved cell therapy products".
3:25 PM on Tuesday, January 31 – Dr. Robert A. Preti, President of PCT, will present during a session titled "Cell therapy and tissue engineered product translational R&D strategy: What advice can companies that have successfully advanced into clinical trials impart?"
About NeoStem, Inc.NeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, Inc., also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-00
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved